Financhill
Back

Mirati Therapeutics 10K Form

Buy
53

MRTX
Mirati Therapeutics

Last Price:
52.56
Seasonality Move:
-5.31%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MRTX News And Ratings

See the #1 stock for the next 7 days that we like better than MRTX

MRTX Financial Statistics

Sales & Book Value

Annual Sales: $72.09M
Cash Flow: $-139.05M
Price / Cash Flow: 0
Annual Sales: $19.61
Price / Book: 2.68

Profitability

EPS (TTM): -13.39000
Net Income (TTM): $-739.61M
Gross Margin: $409.68M
Return on Equity: -61.93%
Return on Assets: -54.02%

Mirati Therapeutics Earnings Forecast

Key Mirati Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for MRTX is 568.29%.
  • The Selling, General & Administrative Expenses for MRTX have been equal to 189.60% of Gross Profit Margin.
  • The Research & Development expenses have been 705.49% of Revenue.
  • The Interest Expense is -0.28% of Operating Income.
  • The Net Earning history of MRTX is -807.99% of Total Revenues.
  • Per Share Earnings over the last 19 years have been positive in 6 years.

Mirati Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: MRTX
CUSIP: 60468T
Website: mirati.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.65
Quick Ratio: 9.47

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MRTX Technical Analysis vs Fundamental Analysis

Buy
53
Mirati Therapeutics (MRTX) is a Buy

Is Mirati Therapeutics a Buy or a Sell?